Hemophilia A is a hereditary bleeding disorder due to factor VIII deficiency. With the advances in the treatment of hemophilia in recent years, the average life expectancy of patients has reached the healthy population. Along with prolonged life, additional diseases and intervention requirements are developing in this patient group. Due to the developments, management of patients going under interventions are more clear and easier. In this case, a patient who underwent an intervention with extended half-life factor therapy was presented.

Forty-three-year-old male patient with severe hemophilia A was evaluated on request for circumcision surgery while using prophylactically extended half-life factor therapy 2 × 1000 Units / week. Tranexamic acid was started one day preoperatively to the patient whose basal factor level was below 1% and whose inhibitory level was negative. Body weight of the patient was 63 kg. Extended half-life factor VIII preparation (efmorogtocog alfa) loading dose of 3000 units was administered befrore half an hour of the procedure. aPtt was detected for 30 seconds and factor VIII level was 55% 30 minutes after loading dose. The patient was given appropriate sedative treatment to prevent pre-perioperative erection. The operation was carried out without any problems. 1500 Units 12 hours after the loading dose, and 24 hours after this dose was performed. The patient was discharged without complications without bleeding. Factor therapy was continued with prophylaxis dosing. Tranexamic acid was continued for 7 days. No complications were observed.

Interventional procedures of hemophilia patients can be performed without complications with a multidisciplinary approach under appropriate dose and scheme factor therapy. In the case, an interventinal procedure was made by giving an extended half-life factor to a severe hemophilia patient who could not have a circumcision operation for many years due to previous hesitations of both patient and surgeons. ,